Current progress in antimalarial pharmacotherapy and multi-target drug discovery

Area of Science:

• Medicinal Chemistry
• Parasitology
• Pharmacology

Background:

• Antimalarial drug discovery traditionally focused on single-target therapies.
• The emergence of drug-resistant malaria strains necessitates novel therapeutic strategies.
• Combination therapy, while effective, also faces resistance challenges.

Purpose of the Study:

• To review current antimalarial pharmacotherapy and identify key targets in the malaria parasite.
• To explore the rationale and development of multi-targeted antimalarial therapies.
• To discuss the concept and examples of covalent biotherapy for malaria.

Main Methods:

• Literature review of antimalarial drug discovery and development.
• Analysis of conventional and novel drug targets in Plasmodium parasites.
• Enumeration and discussion of hybrid antimalarial molecules and their multi-target functionalities.

Main Results:

• Single-target therapies are increasingly ineffective due to drug resistance.
• Multi-target approaches, particularly covalent biotherapy, offer a promising strategy.
• Hybrid molecules with chemically bound pharmacophores demonstrate potential for enhanced efficacy.

Conclusions:

• Covalent biotherapy represents a novel paradigm for developing next-generation antimalarial drugs.
• Multi-target drugs are crucial for overcoming resistance and improving malaria treatment outcomes.
• Further research into hybrid antimalarial agents is warranted to combat the global malaria burden.